UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Find starter accounts offering high interest and learn how to compare introductory yields and account features quickly.
25,613 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
GameStop is weighing a bold move: acquiring eBay. This article breaks down whether does Gamestop's proposed acquisiti...
A clear, investor-friendly look at Sonida's Q1 2026 performance. We unpack the numbers, the drivers behind them, and ...
Investors relying on monthly income from the Vanguard Intermediate-Term Corporate Bond Index Fund ETF are evaluating ...
Two dividend stocks double right now can help steady your income while you grow wealth. We break down two dependable ...
GameStop outperforms other meme stocks in 2026, climbing as speculative bets and buyout chatter around Ryan Cohen fue...
Bitcoin ETFs drew the most cash last week, with ETH and XRP also posting inflows. Here’s the latest breakdown on whic...
As roughly $1.8 billion in crypto options approach expiration on Deribit, traders weigh whether will markets continue...
When headlines shout about dream finders homes struggles, investors should look past the noise and examine the fundam...
When a bank’s CEO retiires and a director sells shares, investors take notice. This article breaks down what that mov...
Cruise stocks are among the S&P 500’s biggest decliners as Middle East tensions and higher fuel costs bite into deman...
As brookfield corp's next earnings approaches, investors weigh how the company will navigate its diverse asset mix. T...